Chabak Vaccine Research Institute Obtains Canadian Patent for Immune Enhancer 'Lipo-Pam'

Simultaneous Immune Enhancement and Antigen Delivery
"Developing Next-Generation Vaccines with Patented Technology... Commercialization Underway"

Cha Vaccine Institute announced on the 14th that it has obtained a Canadian patent for 'a vaccine adjuvant containing liposomes with inserted lipopeptides as active ingredients and its use.'

Chabacsin Research Institute CI. [Image provided by Chabacsin Research Institute]

This patent pertains to vaccines and their manufacturing methods utilizing 'Lipo-pam,' an immune-enhancing platform independently developed by Cha Vaccine Institute. The institute explained that using Lipo-pam with antigens for shingles, Japanese encephalitis, and seasonal influenza viruses has been recognized to enhance both humoral and cellular immune responses.

Lipo-pam is a liposomal formulation of 'L-pampo,' an immune-enhancing platform developed by Cha Vaccine Institute, and is an immune adjuvant in the form of lipid nanoparticles (LNP). It forms the TLR2/TLR3 ligands, the immune-enhancing active substances of L-pampo, into liposomes, inducing strong humoral as well as cellular immune responses. It can also be used as a delivery vehicle for DNA or messenger RNA (mRNA), making it useful for mRNA vaccine development.

Cha Vaccine Institute applied Lipo-pam to 'CVI-VZV-001,' a shingles vaccine candidate currently undergoing Phase 1 clinical trials in Korea. Additionally, it has been applied to various vaccines in preclinical stages, including those for Japanese encephalitis, seasonal influenza, cancer, and norovirus.

Cha Vaccine Institute has obtained patents for Lipo-pam in Australia (March 2022), Japan (May 2022), and the United States (May 2023), and is currently undergoing patent examinations in China and Europe.

Jung-sun Yeom, CEO of Cha Vaccine Institute, stated, "With this patent acquisition, the excellence of Cha Vaccine Institute's immune adjuvants has been recognized not only domestically but also in the global market. Based on this patented technology, we will develop various vaccines and promote commercialization through technology transfer."